Literature DB >> 12234618

Regulation of anandamide tissue levels by N-arachidonylglycine.

Sumner H Burstein1, Susan M Huang, Timothy J Petros, Ronald G Rossetti, J Michael Walker, Robert B Zurier.   

Abstract

N-arachidonylglycine (NAGly), the carboxylic analog of the endocannabinoid anandamide, occurs in rat and bovine brain as well as in peripheral sites and shows activity against tonic, formalin-induced pain. It was also observed, using cell membrane preparations, that it inhibits the hydrolytic activity of fatty acid amide hydrolase (FAAH) on anandamide (N-arachidonylethanolamide). These data suggested that it may serve as an endogenous regulator of tissue anandamide concentrations. In this report, we show findings derived from mass spectrometric analyses, indicating that blood levels of anandamide in rats given 10 mg/kg p.o. of NAGly were increased significantly by more than 9-fold when compared with vehicle-treated controls. In vitro evidence in RAW 264.7 cells using a deuterium-labeled NAGly demonstrated that it was not a precursor or source of arachidonic acid for the observed 50% rise in anandamide levels, suggesting that the increase was due to some effect other than increased biosynthesis of anandamide. Moreover, the findings presented here suggest that NAGly can serve as a model for the design of agents to provide pharmacological control of tissue anandamide concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234618     DOI: 10.1016/s0006-2952(02)01301-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

Review 1.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  The Endocannabinoid System and its Modulation by Phytocannabinoids.

Authors:  Vincenzo Di Marzo; Fabiana Piscitelli
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 4.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 5.  Fatty acid amide signaling molecules.

Authors:  Cyrine Ezzili; Katerina Otrubova; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

6.  Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity.

Authors:  Padmanabha V Kattamuri; Rebecca Salmonsen; Catherine McQuain; Sumner Burstein; Hao Sun; Guigen Li
Journal:  Life Sci       Date:  2012-07-20       Impact factor: 5.037

7.  The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Authors:  Anusha Penumarti; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-15       Impact factor: 4.030

Review 8.  Orphan endogenous lipids and orphan GPCRs: a good match.

Authors:  Heather B Bradshaw; Sung Ha Lee; Douglas McHugh
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-18       Impact factor: 3.072

9.  Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92.

Authors:  Da Young Oh; Jung Min Yoon; Mi Jin Moon; Jong-Ik Hwang; Han Choe; Ju Yeon Lee; Jae Il Kim; Sunoh Kim; Hyewhon Rhim; David K O'Dell; J Michael Walker; Heung Sik Na; Min Goo Lee; Hyuk Bang Kwon; Kyungjin Kim; Jae Young Seong
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

10.  N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via canonical pathways.

Authors:  Van B Lu; Henry L Puhl; Stephen R Ikeda
Journal:  Mol Pharmacol       Date:  2012-10-25       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.